WPV01 / Westlake Pharma, Insilico Medicine - LARVOL DELTA

Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection (clinicaltrials.gov) - P2 | N=80 | Completed | Sponsor: Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19 (clinicaltrials.gov) - P3 | N=1350 | Completed | Sponsor: Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Feb 2024 ➔ Sep 2023 | Trial primary completion date: Jan 2024 ➔ Aug 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19 (clinicaltrials.gov) - P3 | N=1350 | Recruiting | Sponsor: Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

New P3 trial • Infectious Disease • Novel Coronavirus Disease

Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China. (PubMed, Eur J Med Chem) - "Small molecule inhibitors (remdesivir, Paxlovid, and molnupiravir) are essential complements to vaccines and play important roles in clinical treatment of SARS-CoV-2...We review development of small molecule anti-SARS-CoV-2 drugs (azvudine [approved by the NMPA of China on July 25, 2022], VV116 [approved by the NMPA of China on January 29, 2023], FB2001, WPV01, pentarlandir, and cepharanthine) in China and summarize their pharmacological activity, potential mechanisms of action, clinical trials and use, and important milestones in their discovery. The role of structural biology in drug development is also reviewed. Future studies should focus on development of diverse second-generation inhibitors with excellent oral bioavailability, superior plasma half-life, increased antiviral activity against SARS-CoV-2 and its variants, high target specificity, minimal side effects, reduced drug-drug interactions, and improved lung histopathology."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Westlake Pharmaceuticals (Hangzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Westlake Pharmaceuticals (Hangzhou) Co., Ltd.

New P2 trial • Infectious Disease • Novel Coronavirus Disease